Table 2.

Secondary prevention trials of statins including elderly patients

							Result of primary outcome
Study	Agents	Follow-up	Elderly participants	Women	Inclusion criteria	Primary outcome measures	Incidence in active group	Incidence in placebo group	ARRP value
4S [1]	Simvastatin 20 mg vs. placebo	5.4 years	≥60 years (51.3%)	18.6%	Previous CHD	All-cause mortality	8.2%	11.5%	3.3%P = 0.0003
CARE [2]	Pravastatin 40 mg vs. placebo	5 years	≥60 years (51.1%)	14.0%	Previous MI	CHD death and nonfatal MI	10.2%	13.2%	3.0%P = 0.003
LIPID [3]	Pravastatin 40 mg vs. placebo	6.1 years	65–69 years (24.0%) ≥70 years (15.0%)	17.0%	Previous MI or hospitalization for UA	CHD death	12.3%	15.9%	3.6%P < 0.001
HPS [13]	Simvastatin 40 mg vs. placebo	5 years	65–69 years (25.0%) 70–74 yearS (22.0%) >74 yearS (6.0%)	24.7%	CVD, DM, or treated HT	Cardiovascular and all- cause mortality	12.9%	14.7%	1.8%P = 0.0003
PROSPER [14]	Pravastatin 40 mg vs. placebo	3.2 years	>65 years (100%)	48.3%	Subjects with CVD or at high CVD risk	Combined endpoint of CHD death, MI, and fatal and nonfatal stroke	14.1%	16.2%	2.1%P = 0.014

CVD cardiovascular disease; MI myocardial infarction; UA unstable angina; CHD coronary heart disease; HT hypertension; DM diabetes mellitus; ARR absolute risk reduction.